Retrospective Study
Copyright ©The Author(s) 2017.
World J Nephrol. May 6, 2017; 6(3): 150-161
Published online May 6, 2017. doi: 10.5527/wjn.v6.i3.150
Table 6 Comparison of clinical characteristic, laboratory abnormalities and complications between survival and non survival group (n = 88)
Survived (n = 79)Died (n = 9)P valuea
Oliguria, n (%)62 (78.5)8 (88.9)0.679
Hematuria, n (%)44 (55.7)4 (44.4)0.726
Anemia, n (%)64 (81)7 (77.8)1.000
Leukocytosis, n (%)57 (72.2)9 (100)0.105
Thrombocytopenia, n (%)37 (46.8)5 (55.6)0.731
Hyperkalemia, n (%)19 (24.1)3 (33.3)0.685
Metabolic acidosis, n (%)29 (36.7)6 (66.7)0.147
Hypoalbuminemia, n (%)46 (58.2)8 (88.9)0.145
Hepatic dysfunction, n (%)32 (40.5)4 (44.4)1.000
Hemolysis, n (%)67 (84.8)8 (88.9)1.000
Rhabdomyolysis, n (%)55 (69.6)5 (55.6)0.457
Pneumonia/ARDS, n (%)3 (3.8)5 (55.6)0.001
Seizure/Encephalopathy, n (%)5 (6.3)4 (44.1)0.005
Multiorgan failure, n (%)2 (2.5)2 (22.2)0.050
ICU support, n (%)5 (6.3)5 (55.6)0.001
Dialysis, n (%)57 (72.2)9 (100)0.105